Sep 19 2025 This Week in Cardiology

This Week in Cardiology

Medscape Podcasts

Medicine, Science, Health & Fitness

4.9 • 963 Ratings

🗓️ 19 September 2025

⏱️ 34 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I PARACHUTE HF

First Evidence of Treatment Benefit in Chagas Heart Failure

https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem

PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021

II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial

Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q

DAPA ACT HF-TIMI 68

https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575

III AMALFI Trial of AF Screening

Remote ECG Screening Ups Atrial Fibrillation Detection 'Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx

AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482
STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext
LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link

IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy

Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090
Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Transcript

Click on a timestamp to play from that location

0:00.0	You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology.
0:05.7	This podcast is intended for health care professionals only.
0:08.8	Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape.
0:15.0	Hi, everyone.
0:16.8	This is John Mandrola from the heart.org medscape cardiology,
0:20.4	and this is this week in cardiology for September 19th, 2025.
0:25.8	This week, a couple more trials at ESC. This includes parachute, DAPA ACT, heart failure, amalfi,
0:34.4	and also a super interesting modeling study of when to start oral anticoagulation and
0:40.3	atrial fibrillation.
0:42.3	So the first topic is the first evidence of treatment benefit in Shagas heart failure.
0:48.0	That's the title of the news story.
0:50.6	The study was called the Parachute HF trial.
0:57.6	Sacubitruvelsartan, brand name Entresto,
1:04.4	has struggled to find a positive trial after Paradigm HF, which compared high-dose saccubitral Val-Sartan to medium dose in alapril in patients with Hefref. All other trials with Saccubitral Val-Sartan, including Paragon,
1:14.8	and Paradise, have been non-significant. At the ESC meeting, we heard results of the Parachute
1:21.8	HF trial, and this was Saccubitril Val-Sartan versus analypril in patients with Shagas cardiomyopathy.
1:29.5	The results were positive, but there were many, many caveats to discuss.
1:35.0	And even if you don't see patients with Shagas disease,
1:38.6	it is worth dissecting this trial for its critical appraisal lessons.
1:43.0	Sadly, I think it may also tempt you to be a bit
1:45.7	cynical in the process. So first, I'll do some background, then the trial design issues, then the
1:52.0	results in interpretation. So the background, Shagas cardiomyopathy is the late effect of infection
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.